Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans
Treatment with senescence-targeting therapy improves BM hematopoietic stem and progenitor cells in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high quality bespoke clinical products, and potentially enhance the safety...